Tag: ASCO 2016
Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...
Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E, presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...
Astellas Presents Study-results of two Investigational ADCs in Patients with Metastatic...
With two approved antibody-drug conjugates and a large number of ADCs in clinical development scientists have made significant advances bringing novel ADC technology to the forefront...
AbbVie Demonstrates Progress in Oncology Research at ASCO 2016
Chemotherapy remains the standard of care in the treatment of many types of cancer. However, one of the problems with chemotherapeutics is that it...
Clinical Updates Confirming Advances and Meaningful Benefits for Patients
Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...
ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...
Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...
